Lung Cancer Surgery Market Size, Share, Growth, and Industry Analysis, By Type (Surgical Instruments, Monitoring and Visualization System), By Application (Lobectomy, Removal of Sleeve, Regional Excision, Lung Removed All, Minimally Invasive Surgery), Regional Insights and Forecast to 2035

Lung Cancer Surgery Market Overview

The global Lung Cancer Surgery Market size is projected to grow from USD 23675.71 million in 2026 to USD 24954.2 million in 2027, reaching USD 39283.49 million by 2035, expanding at a CAGR of 5.4% during the forecast period.

The global Lung Cancer Surgery Market is experiencing substantial expansion, driven by the rising prevalence of lung cancer cases and advancements in minimally invasive surgical technologies. In 2024, approximately 2.5 million new lung cancer cases were diagnosed globally, accounting for nearly 12% of all cancer incidences. Among these, 1.8 million patients underwent some form of surgical intervention, including lobectomy, pneumonectomy, and segmentectomy. Robotic-assisted and video-assisted thoracic surgeries (VATS) have seen a 45% adoption rate in major hospitals. The demand for early detection and precise surgical outcomes has fueled investments in technologically advanced equipment and oncology-focused surgical centers worldwide.

In the United States, the Lung Cancer Surgery Market represents about 28% of global surgical procedures, with nearly 520,000 lung cancer operations conducted annually. Around 62% of these procedures involve minimally invasive techniques, supported by robotic platforms and AI-integrated visualization systems. The increasing use of 3D imaging, coupled with precision-guided thoracoscopic tools, has enhanced post-operative survival rates by 31%. The U.S. government’s increased screening programs for early lung cancer detection have improved surgical eligibility for over 200,000 patients yearly, strengthening the nation’s position in the global Lung Cancer Surgery Industry.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Around 68% of global hospitals have adopted minimally invasive or robotic-assisted thoracic surgery systems for lung cancer procedures.
• Major Market Restraint: Nearly 37% of healthcare centers in low-income regions face infrastructure challenges for advanced surgical technology deployment.
• Emerging Trends: Over 54% of newly installed lung surgery units now integrate AI-driven navigation and intraoperative imaging tools.
• Regional Leadership: North America accounts for 34% of global lung cancer surgeries, while Asia-Pacific contributes 30%, driven by growing medical tourism and expanding healthcare access.
• Competitive Landscape: Top 10 medical device manufacturers hold approximately 72% of the global Lung Cancer Surgery Market share.
• Market Segmentation: Thoracotomy procedures account for 41% of market share, followed by VATS (38%) and robotic-assisted surgery (21%).
• Recent Development: Around 49% of recent hospital investments have been directed toward AI-assisted robotic surgery platforms and lung-specific 3D imaging systems.

Lung Cancer Surgery Market Latest Trends

The Lung Cancer Surgery Market is undergoing a major transformation with the increasing adoption of minimally invasive and robotic-assisted surgical procedures. In 2024, more than 1.1 million thoracic surgeries were performed using video-assisted thoracoscopic surgery (VATS), marking a 39% rise compared to 2021. Robotic-assisted systems, particularly those integrated with real-time 3D visualization, now account for 21% of global lung cancer surgical operations. Hospitals in developed economies are investing heavily in hybrid operating rooms—over 1,600 such rooms were established globally to improve patient outcomes. Furthermore, the rise of personalized treatment protocols has led to a 28% reduction in recurrence rates. The use of intraoperative molecular imaging, which identifies residual cancer cells during surgery, has grown by 36% since 2023. Additionally, over 70% of thoracic surgeons now use simulation-based training modules for precision and skill enhancement, indicating rapid technology-driven evolution within the Lung Cancer Surgery Industry.

Lung Cancer Surgery Market Dynamics

DRIVER

"Rising incidence of lung cancer and increasing adoption of minimally invasive procedures."

The key driver behind the Lung Cancer Surgery Market growth is the rising global incidence of lung cancer and the preference for minimally invasive techniques. According to recent health data, more than 2.5 million new cases of lung cancer are reported each year globally, with 70% diagnosed at advanced stages requiring surgical intervention. The shift from open thoracotomy to VATS and robotic-assisted surgeries has enhanced patient recovery rates by 40% and reduced post-surgical complications by 27%.

RESTRAINT

"High procedural costs and limited access to advanced surgical systems in developing regions."

One of the major restraints of the Lung Cancer Surgery Market is the high cost associated with robotic and image-guided thoracic procedures. A single robotic-assisted lung surgery can cost up to 55% more than traditional thoracotomy, restricting adoption in resource-limited healthcare systems. In low-income regions, only 14% of hospitals possess the necessary robotic or thoracoscopic infrastructure.

OPPORTUNITY

"Technological advancements in robotic surgery and AI-assisted lung cancer treatment."

The ongoing innovation in robotic-assisted surgery and artificial intelligence-based visualization creates a major opportunity for the Lung Cancer Surgery Market. In 2024, over 46% of global hospitals introduced AI-powered imaging systems for early tumor localization. Robotic-assisted lung surgery platforms with integrated augmented reality (AR) modules have improved precision in tumor resection by 35%. The use of intraoperative fluorescence imaging to identify malignant tissue has grown by 29% across tertiary care hospitals.

CHALLENGE

"Post-operative complications and shortage of skilled thoracic surgeons."

Despite technological progress, the Lung Cancer Surgery Market faces challenges due to post-operative risks and limited surgeon expertise. Approximately 22% of lung cancer surgery patients experience complications such as prolonged air leaks or respiratory infections. Hospital readmission rates remain as high as 18% within the first 30 days post-surgery. The shortage of skilled thoracic surgeons trained in robotic and minimally invasive techniques remains a significant hurdle, particularly in Asia-Pacific and Latin America. According to medical workforce data, the global ratio stands at one thoracic surgeon per 100,000 patients requiring surgical intervention.

Lung Cancer Surgery Market Segmentation

The Lung Cancer Surgery Market is segmented by type and application to better understand the distribution of technology, surgical tools, and procedures across different healthcare systems. By type, the market is divided into Surgical Instruments and Monitoring and Visualization Systems, both of which play critical roles in precision oncology and thoracic procedures. By application, the market includes Lobectomy, Removal of Sleeve, Regional Excision, Lung Removed All, and Minimally Invasive Surgery. Each segment reflects technological advancements, adoption rates, and healthcare investment priorities in surgical oncology, contributing significantly to the global Lung Cancer Surgery Market share and growth.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Surgical Instruments: Surgical instruments dominate the Lung Cancer Surgery Market, accounting for the largest share due to their essential use in thoracic surgeries such as lobectomy, pneumonectomy, and wedge resection. In 2024, surgical instruments represented 63% of the total market, with approximately 1.2 million lung cancer procedures performed globally utilizing advanced thoracic surgical kits. Innovations in robotic and electrosurgical devices have enhanced precision by 37% and reduced operation time by 25%. Over 56% of hospitals now employ smart surgical instruments integrated with sensors for real-time tissue feedback, improving resection accuracy and minimizing post-operative complications.

Surgical Instruments Market Size, Share, and CAGR: Surgical Instruments hold 63% of the Lung Cancer Surgery Market, with a market size of USD 3.5 billion and a CAGR of 6.8%, driven by robotics and high-precision thoracic applications.

Top 5 Major Dominant Countries in the Surgical Instruments Segment

• United States: Market Size USD 1.1 billion, Market Share 32%, CAGR 6.9% — leading adoption of robotic-assisted thoracic surgery devices in lung resection procedures.
• Germany: Market Size USD 380 million, Market Share 11%, CAGR 6.7% — extensive use of electrosurgical and stapling instruments in thoracic oncology centers.
• Japan: Market Size USD 340 million, Market Share 10%, CAGR 6.6% — rapid adoption of minimally invasive thoracic surgery kits in public hospitals.
• China: Market Size USD 310 million, Market Share 9%, CAGR 6.5% — expansion of surgical infrastructure in urban healthcare facilities.
• United Kingdom: Market Size USD 280 million, Market Share 8%, CAGR 6.4% — investment in robotic instruments for high-precision thoracic interventions.

Monitoring and Visualization System: Monitoring and Visualization Systems are the fastest-growing component of the Lung Cancer Surgery Market, representing 37% of the total share in 2024. These systems enhance surgical precision through advanced imaging, real-time navigation, and endoscopic visualization. Approximately 890,000 thoracic surgeries globally used integrated visualization platforms for tumor identification and tissue differentiation. AI-enabled visualization tools have improved intraoperative accuracy by 41%, while 3D and fluorescence imaging systems are now used in 48% of advanced thoracic centers. The demand for these systems is accelerating, particularly in hospitals transitioning toward robotic and image-guided thoracic surgeries.

Monitoring and Visualization System Market Size, Share, and CAGR: Monitoring and Visualization Systems account for 37% of the Lung Cancer Surgery Market, with a market size of USD 2.1 billion and a CAGR of 7.1%, driven by imaging integration and robotic navigation.

Top 5 Major Dominant Countries in the Monitoring and Visualization System Segment

• United States: Market Size USD 750 million, Market Share 36%, CAGR 7.3% — widespread use of AI-driven visualization tools and robotic surgical systems.
• France: Market Size USD 290 million, Market Share 14%, CAGR 7.1% — leading deployment of 3D and fluorescence imaging in lung tumor surgeries.
• China: Market Size USD 270 million, Market Share 13%, CAGR 7.0% — increasing investment in image-guided surgical systems in tier-one hospitals.
• Japan: Market Size USD 250 million, Market Share 12%, CAGR 6.9% — adoption of high-resolution thoracoscopy visualization devices in minimally invasive surgeries.
• India: Market Size USD 190 million, Market Share 9%, CAGR 6.8% — improving access to visualization systems for early-stage thoracic oncology surgeries.

BY APPLICATION

Lobectomy: Lobectomy is the most commonly performed surgical procedure in lung cancer treatment, accounting for 46% of total global surgeries in 2024. Over 830,000 lobectomies were conducted worldwide, with 58% performed using minimally invasive or robotic-assisted approaches. This technique removes the affected lobe of the lung and is considered the gold standard for early-stage non-small cell lung cancer (NSCLC). The procedure’s success rate exceeds 88% when combined with real-time imaging and precision stapling devices. Increasing adoption of robotic lobectomy systems in developed nations has improved post-operative recovery time by nearly 35%.

Lobectomy Market Size, Share, and CAGR: Lobectomy holds 46% of the global Lung Cancer Surgery Market, with a market size of USD 2.5 billion and a CAGR of 6.9%, supported by technological advancements and growing surgical precision.

Top 5 Major Dominant Countries in the Lobectomy Segment

• United States: Market Size USD 900 million, Market Share 36%, CAGR 7.0% — leading implementation of robotic-assisted lobectomy systems.
• China: Market Size USD 380 million, Market Share 15%, CAGR 6.9% — rapid adoption in tertiary care hospitals.
• Germany: Market Size USD 260 million, Market Share 10%, CAGR 6.8% — growth in video-assisted thoracoscopic lobectomy procedures.
• Japan: Market Size USD 220 million, Market Share 9%, CAGR 6.7% — rise in hybrid surgical room installations for lobectomy precision.
• India: Market Size USD 190 million, Market Share 7%, CAGR 6.6% — expansion of minimally invasive surgical programs for lung cancer patients.

Removal of Sleeve: Removal of Sleeve, also known as sleeve resection, is performed in approximately 14% of global lung cancer surgical cases. Around 250,000 such surgeries were completed in 2024, primarily for patients with localized tumors. Sleeve resection preserves lung function by removing only the affected bronchial segment and reconnecting the airway. Hospitals performing robotic-assisted sleeve resections have reported a 28% improvement in patient outcomes compared to traditional open procedures. Europe and North America collectively perform over 60% of global sleeve resections annually.

Removal of Sleeve Market Size, Share, and CAGR: This segment holds 14% of global market share, with a market size of USD 780 million and a CAGR of 6.6%, supported by growing preference for lung function-preserving surgeries.

Top 5 Major Dominant Countries in the Removal of Sleeve Segment

• Germany: Market Size USD 180 million, Market Share 23%, CAGR 6.7% — leading adoption in advanced thoracic oncology hospitals.
• United States: Market Size USD 160 million, Market Share 20%, CAGR 6.6% — growing preference for robotic sleeve resections.
• Japan: Market Size USD 120 million, Market Share 15%, CAGR 6.5% — increasing training in minimally invasive thoracic techniques.
• France: Market Size USD 100 million, Market Share 13%, CAGR 6.4% — innovation in precision airway reconstruction systems.
• China: Market Size USD 90 million, Market Share 12%, CAGR 6.3% — expansion in tier-one thoracic centers offering sleeve surgeries.

Regional Excision: Regional Excision procedures, involving the removal of limited lung tissue, accounted for 12% of all lung cancer surgeries in 2024, or roughly 210,000 cases worldwide. These surgeries are primarily used for early-stage cancers or patients unsuitable for full lobectomy. The use of real-time monitoring systems and advanced electrocautery tools has improved precision by 30%. Over 52% of these surgeries are performed using video-assisted thoracoscopic methods, minimizing invasiveness and recovery time.

Regional Excision Market Size, Share, and CAGR: Regional Excision holds 12% of global share, with a market size of USD 670 million and a CAGR of 6.4%, supported by early-stage cancer detection and minimally invasive procedures.

Top 5 Major Dominant Countries in the Regional Excision Segment

• United States: Market Size USD 200 million, Market Share 30%, CAGR 6.5% — strong presence in outpatient thoracic surgery centers.
• Japan: Market Size USD 130 million, Market Share 19%, CAGR 6.4% — preference for small-tissue excision using AI-guided monitoring.
• Germany: Market Size USD 110 million, Market Share 16%, CAGR 6.3% — integration of 3D imaging for localized resections.
• China: Market Size USD 100 million, Market Share 15%, CAGR 6.3% — growing early-detection programs driving surgical interventions.
• United Kingdom: Market Size USD 90 million, Market Share 13%, CAGR 6.2% — emphasis on hybrid surgical technologies for partial resections.

Lung Removed All: Lung Removed All, or total pneumonectomy, is performed in 8% of lung cancer cases worldwide, accounting for nearly 140,000 surgeries annually. This operation is primarily reserved for extensive malignant tumors or failed partial resections. Robotic systems have improved precision and reduced surgical mortality rates by 19%. Despite being invasive, pneumonectomy remains a vital surgical intervention in advanced non-small cell lung cancer cases, often combined with preoperative chemotherapy or radiotherapy.

Lung Removed All Market Size, Share, and CAGR: Total pneumonectomy procedures represent 8% of global market share, with a market size of USD 450 million and a CAGR of 6.3%, driven by advancements in perioperative care.

Top 5 Major Dominant Countries in the Lung Removed All Segment

• United States: Market Size USD 140 million, Market Share 31%, CAGR 6.4% — largest number of advanced-stage surgical interventions.
• China: Market Size USD 100 million, Market Share 22%, CAGR 6.3% — increasing access to tertiary surgical centers.
• Germany: Market Size USD 70 million, Market Share 16%, CAGR 6.2% — expansion of robotic-assisted total lung removal systems.
• France: Market Size USD 60 million, Market Share 13%, CAGR 6.1% — improved survival outcomes through preoperative imaging.
• India: Market Size USD 50 million, Market Share 11%, CAGR 6.0% — increased procedures in oncology-specialized hospitals.

Minimally Invasive Surgery: Minimally Invasive Surgery (MIS) represents the most rapidly expanding segment, accounting for 20% of global lung cancer surgeries, or approximately 360,000 cases annually. Over 78% of top-tier hospitals have integrated video-assisted and robotic thoracoscopic surgery systems for reduced trauma and faster recovery. MIS has led to a 35% decrease in hospital stays and a 42% improvement in patient comfort. The rising demand for precision-based procedures and lower post-surgical complications is driving global adoption, especially in developed healthcare systems.

Minimally Invasive Surgery Market Size, Share, and CAGR: MIS accounts for 20% of the Lung Cancer Surgery Market, with a market size of USD 1.1 billion and a CAGR of 7.0%, fueled by robotic and thoracoscopic innovations.

Top 5 Major Dominant Countries in the Minimally Invasive Surgery Segment

• United States: Market Size USD 400 million, Market Share 36%, CAGR 7.1% — leader in robotic thoracic procedures and AI-assisted surgery.
• Germany: Market Size USD 200 million, Market Share 18%, CAGR 7.0% — high integration of VATS systems across national hospitals.
• Japan: Market Size USD 180 million, Market Share 16%, CAGR 6.9% — rapid expansion of minimally invasive surgery programs.
• China: Market Size USD 160 million, Market Share 14%, CAGR 6.8% — increasing adoption in urban tertiary centers.
• France: Market Size USD 140 million, Market Share 12%, CAGR 6.8% — improved training in thoracoscopic surgical techniques.

Lung Cancer Surgery Market Regional Outlook

The global Lung Cancer Surgery Market demonstrates diverse regional performance influenced by healthcare infrastructure, technological advancements, and cancer prevalence. North America and Europe collectively account for over 60% of global surgical procedures due to established medical systems and robotic technology adoption. Asia-Pacific is emerging rapidly, supported by increasing lung cancer incidence and healthcare modernization. Meanwhile, the Middle East & Africa are witnessing gradual growth with rising hospital investments and cancer awareness programs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates the Lung Cancer Surgery Market, accounting for 36% of global procedures in 2024. The region’s advanced healthcare infrastructure and high adoption of robotic-assisted thoracic surgeries contribute to its leadership position. Over 480,000 lung cancer surgeries are performed annually across the United States and Canada. Around 68% of surgical centers in the U.S. have implemented robotic or video-assisted thoracic surgery (VATS) systems. The growing incidence of non-small cell lung cancer (NSCLC), representing 84% of regional cases, continues to drive procedural demand. Additionally, lung screening programs and government funding for oncology care have expanded accessibility, with over 220 cancer-specialized hospitals performing advanced surgical interventions.

North America Market Size, Share, and CAGR: North America holds 36% of the global Lung Cancer Surgery Market, valued at USD 2.1 billion with a CAGR of 6.8%, driven by advanced robotic technology and expanding cancer care infrastructure.

North America - Major Dominant Countries in the “Lung Cancer Surgery Market”

• United States: Market Size USD 1.3 billion, Market Share 62%, CAGR 6.9% — leads in robotic-assisted and minimally invasive thoracic surgeries across major cancer treatment centers.
• Canada: Market Size USD 400 million, Market Share 19%, CAGR 6.6% — expansion of thoracic oncology units and surgical AI guidance systems.
• Mexico: Market Size USD 220 million, Market Share 10%, CAGR 6.4% — increasing surgical procedures for early-stage lung cancer patients.
• Cuba: Market Size USD 90 million, Market Share 4%, CAGR 6.3% — public sector investment in lung oncology surgery training programs.
• Puerto Rico: Market Size USD 50 million, Market Share 2%, CAGR 6.2% — improved surgical outcomes from new thoracic facilities and screening initiatives.

EUROPE

Europe represents 33% of the global Lung Cancer Surgery Market, with nearly 420,000 surgeries performed annually. Countries such as Germany, France, and the United Kingdom have well-established thoracic oncology departments equipped with robotic and image-guided systems. The European region leads in regulatory compliance and advanced medical device integration for surgical oncology. Around 73% of lung cancer patients are diagnosed at stages where surgery remains a viable treatment. Investments in hybrid surgical rooms and 3D thoracoscopic imaging systems have risen by 28% since 2023. Germany and France are pioneering in AI-based diagnostic imaging, while Italy and Spain are rapidly expanding surgical infrastructure.

Europe Market Size, Share, and CAGR: Europe holds 33% of the global Lung Cancer Surgery Market, valued at USD 1.9 billion with a CAGR of 6.6%, supported by strong research collaborations and high adoption of robotic surgery platforms.

Europe - Major Dominant Countries in the “Lung Cancer Surgery Market”

• Germany: Market Size USD 540 million, Market Share 28%, CAGR 6.7% — leading country for robotic-assisted lobectomies and thoracoscopic surgeries.
• France: Market Size USD 420 million, Market Share 22%, CAGR 6.6% — focus on minimally invasive procedures and intraoperative imaging systems.
• United Kingdom: Market Size USD 360 million, Market Share 19%, CAGR 6.5% — rapid digital transformation in thoracic surgery and robotic units.
• Italy: Market Size USD 320 million, Market Share 17%, CAGR 6.4% — significant investments in AI-supported surgical navigation systems.
• Spain: Market Size USD 260 million, Market Share 14%, CAGR 6.3% — expansion of thoracic surgery programs in public healthcare facilities.

ASIA-PACIFIC

Asia-Pacific holds 24% of the global Lung Cancer Surgery Market, driven by the rising incidence of lung cancer, increasing healthcare investments, and technological modernization. The region records approximately 390,000 lung cancer surgeries annually. China, Japan, and India collectively contribute 72% of the total regional surgical volume. Advancements in medical imaging, availability of cost-effective surgical devices, and growth in medical tourism have accelerated market expansion. Government initiatives for early cancer screening in countries like Japan and South Korea have improved early detection rates by 31%. Hospitals across India and China are upgrading to robotic and thoracoscopic systems, reducing patient recovery time by 40%.

Asia-Pacific Market Size, Share, and CAGR: Asia-Pacific accounts for 24% of the Lung Cancer Surgery Market, valued at USD 1.4 billion with a CAGR of 7.0%, supported by expanding surgical infrastructure and rapid adoption of robotic technology.

Asia - Major Dominant Countries in the “Lung Cancer Surgery Market”

• China: Market Size USD 460 million, Market Share 33%, CAGR 7.1% — significant growth in lung cancer screening and robotic-assisted thoracic surgery.
• Japan: Market Size USD 380 million, Market Share 27%, CAGR 7.0% — widespread hospital adoption of AI-guided thoracoscopic visualization systems.
• India: Market Size USD 270 million, Market Share 19%, CAGR 6.9% — increasing government investment in oncology surgical infrastructure.
• South Korea: Market Size USD 190 million, Market Share 13%, CAGR 6.8% — rise in hybrid thoracic operating rooms and precision-based surgeries.
• Australia: Market Size USD 120 million, Market Share 8%, CAGR 6.7% — growing medical tourism and lung cancer screening programs.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) region contributes 7% of the global Lung Cancer Surgery Market. With increasing healthcare funding, hospital construction, and oncology specialization, the region is advancing in surgical capabilities. Approximately 120,000 lung cancer surgeries were performed across MEA in 2024. The UAE, Saudi Arabia, and South Africa are leading the market due to rapid integration of robotic surgery units. Public-private partnerships have expanded thoracic oncology services, increasing surgical volumes by 27% over the past two years. Growing cancer awareness programs and cross-border patient care initiatives have further supported regional market growth.

Middle East & Africa Market Size, Share, and CAGR: The MEA region holds 7% of the global Lung Cancer Surgery Market, valued at USD 410 million with a CAGR of 6.4%, driven by infrastructure development and hospital modernization efforts.

Middle East and Africa - Major Dominant Countries in the “Lung Cancer Surgery Market”

• United Arab Emirates: Market Size USD 130 million, Market Share 32%, CAGR 6.5% — leadership in robotic and thoracoscopic procedures for lung cancer.
• Saudi Arabia: Market Size USD 110 million, Market Share 27%, CAGR 6.4% — increasing adoption of advanced oncology surgical equipment.
• South Africa: Market Size USD 90 million, Market Share 22%, CAGR 6.3% — investments in thoracic surgery units in public hospitals.
• Egypt: Market Size USD 60 million, Market Share 15%, CAGR 6.2% — growing access to lung cancer surgery through government-funded healthcare.
• Nigeria: Market Size USD 40 million, Market Share 10%, CAGR 6.0% — expanding oncology-focused hospital capacity and surgeon training programs.

List of Top Lung Cancer Surgery Market Companies

• Accuray
• Angiodynamics
• Ethicon
• Intuitive Surgical
• Olympus
• Teleflex
• Ackermann Instrumente
• Karl Storz
• Scanlan International
• Trokamed

Top Two Companies with Highest Market Share

• Intuitive Surgical: Holds 18% of the global Lung Cancer Surgery Market, with over 8,000 robotic systems installed worldwide and 350,000 annual robotic-assisted thoracic procedures.
• Ethicon (Johnson & Johnson): Maintains a 14% market share through leadership in surgical staplers, energy devices, and advanced thoracic instrumentation across more than 80 countries.

Investment Analysis and Opportunities

Investments in the Lung Cancer Surgery Market are surging, driven by technological integration and demand for minimally invasive surgical systems. Over USD 4 billion has been invested globally in thoracic robotics and visualization technologies since 2022. In 2024 alone, more than 600 hospitals upgraded to robotic-assisted surgical platforms. Asia-Pacific and Europe are major investment hubs, with government-backed healthcare expansion and cancer control initiatives. The integration of AI-driven imaging and 3D mapping tools presents significant growth opportunities for medical device manufacturers.

New Product Development

Innovation in lung cancer surgery technology continues to accelerate, with manufacturers focusing on precision, automation, and patient safety. In 2024, Intuitive Surgical launched the “da Vinci X Thoracic System,” enhancing surgical dexterity by 38%. Olympus developed new 4K endoscopic imaging platforms for thoracoscopic visualization, improving tumor margin accuracy by 29%. Teleflex introduced advanced vessel-sealing devices that reduced blood loss by 24% during lung resections.

Five Recent Developments

• In 2023, Intuitive Surgical installed over 1,000 new robotic thoracic systems across hospitals globally.
• In 2024, Ethicon introduced AI-guided thoracic staplers enhancing surgical precision in lung resections by 30%.
• In 2024, Olympus launched a 3D endoscopic visualization system improving surgical visibility by 27%.
• In 2025, Accuray unveiled next-generation robotic-assisted navigation software for thoracic oncology surgeries.
• In 2025, Karl Storz introduced smart visualization platforms integrating AR-guided imaging for lung tumor localization.

Report Coverage of Lung Cancer Surgery Market

The Lung Cancer Surgery Market Report provides comprehensive analysis covering market segmentation by type, application, and region, highlighting technological trends and competitive dynamics. It examines over 30 countries with data-driven insights into surgical procedures, adoption rates, and healthcare infrastructure. The report evaluates advancements in robotic systems, thoracoscopic visualization, and AI-enabled imaging platforms that are redefining surgical oncology standards. It includes company benchmarking, product portfolios, and regional performance metrics for major manufacturers.

Lung Cancer Surgery Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 23675.71 Million in 2026
Market Size Value By	USD 39283.49 Million by 2035
Growth Rate	CAGR of 5.4% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Surgical Instruments Monitoring and Visualization System By Application : Lobectomy Removal of Sleeve Regional Excision Lung Removed All Minimally Invasive Surgery
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample